PMID- 12010330
OWN - NLM
STAT- MEDLINE
DCOM- 20020726
LR  - 20220317
IS  - 0919-8172 (Print)
IS  - 0919-8172 (Linking)
VI  - 9
IP  - 3
DP  - 2002 Mar
TI  - Bilateral testicular tumors: a report of nine cases with long-term follow-up.
PG  - 173-7
AB  - BACKGROUND: The incidence and clinical features of bilateral germ cell testicular 
      tumor (GCTT) in the Japanese population are not fully characterized. We examined 
      the incidence, clinical features, management and outcome, sexual status, hormonal 
      environment, implication of androgen replacement, and human leukocyte antigen 
      (HLA) typing of bilateral GCTT. METHODS: We treated nine consecutive patients 
      with bilateral GCTT from 1980 through to 1999, and reviewed their hospital and 
      clinic charts. Testosterone, luteinizing hormone, follicle stimulating hormone, 
      dehydroepiandrosterone, and dehydroepiandrosterone-sulfate were measured in 
      bilateral orchiectomized patients. Human leukocyte antigen typing was assessed 
      with peripheral lymphocyte. RESULTS: The incidence of bilateral GCTT against the 
      total number of patients with GCTT was 9/274 (3.3%). The median age of the first 
      tumor was 29 (range 21-75) years. Three cases were synchronous and the remaining 
      six cases were metachronous. In the case of metachronous tumor, the median 
      interval between first and contralateral tumor was 8 (range 2-25) years. Standard 
      treatment was defined as surveillance policy in stage I, chemotherapy for higher 
      stages of non-seminoma, and radiotherapy for stage II seminoma. Human leukocyte 
      antigen typing was examined for seven cases. Five cases were positive for 
      HLA-A24. The incidence of HLA-A24 in bilateral GCTT was identical to that of the 
      Japanese population. The relapsing incidence of stage I disease with surveillance 
      policy was almost identical to unilateral GCTT. A 74-year-old patient with stage 
      II seminoma died of the disease at 1.3 years. The other eight patients remained 
      well without any evidence of recurrence at a median follow-up period of 78 (range 
      12-204) months. Four patients with bilateral orchiectomy did not require androgen 
      replacement without easy fatigability. Sexual status was conserved using androgen 
      replacement. CONCLUSIONS: Long-term follow-up, as long as 25 years, is 
      recommended for contralateral relapse. Some patients with bilateral orchiectomy 
      do not require androgen replacement. The significance of HLA-A24 for bilateral 
      testicular tumor is equivocal in the Japanese population.
FAU - Ohyama, Chikara
AU  - Ohyama C
AD  - Department of Urology, Tohoku University School of Medicine, 1-1 Seiryo-machi, 
      Aoba-ku, Sendai 980-8574, Japan. coyama@uro.med.tohoku.ac.jp
FAU - Kyan, Atsushi
AU  - Kyan A
FAU - Satoh, Makoto
AU  - Satoh M
FAU - Saito, Seiichi
AU  - Saito S
FAU - Nishimura, Yosuke
AU  - Nishimura Y
FAU - Imai, Yoshitada
AU  - Imai Y
FAU - Oikawa, Katsuhiko
AU  - Oikawa K
FAU - Yokoyama, Jun
AU  - Yokoyama J
FAU - Suzuki, Kenishi
AU  - Suzuki K
FAU - Takeuchi, Mutsuo
AU  - Takeuchi M
FAU - Hoshi, Senji
AU  - Hoshi S
FAU - Orikasa, Seiichi
AU  - Orikasa S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Australia
TA  - Int J Urol
JT  - International journal of urology : official journal of the Japanese Urological 
      Association
JID - 9440237
RN  - 0 (Androgens)
RN  - 0 (HLA Antigens)
RN  - 3XMK78S47O (Testosterone)
RN  - 9002-68-0 (Follicle Stimulating Hormone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Androgens/therapeutic use
MH  - Follicle Stimulating Hormone/blood
MH  - Follow-Up Studies
MH  - *Germinoma/epidemiology/pathology/therapy
MH  - HLA Antigens/blood
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Orchiectomy
MH  - *Testicular Neoplasms/epidemiology/pathology/therapy
MH  - Testosterone/blood
EDAT- 2002/05/16 10:00
MHDA- 2002/07/27 10:01
CRDT- 2002/05/16 10:00
PHST- 2002/05/16 10:00 [pubmed]
PHST- 2002/07/27 10:01 [medline]
PHST- 2002/05/16 10:00 [entrez]
AID - 446 [pii]
AID - 10.1046/j.1442-2042.2002.00446.x [doi]
PST - ppublish
SO  - Int J Urol. 2002 Mar;9(3):173-7. doi: 10.1046/j.1442-2042.2002.00446.x.